AstraZeneca's DATROWAY Gains FDA Nod for Metastatic Triple-Negative Breast Cancer

Event summary

  • DATROWAY (datopotamab deruxtecan-dlnk) approved by FDA for 1st-line treatment of metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-1/PD-L1 inhibitors.
  • Approval based on TROPION-Breast02 trial showing 5.0-month median overall survival improvement over chemotherapy.
  • DATROWAY now approved for three US indications, including two for breast cancer.
  • Trial demonstrated 64% objective response rate vs. 30% with chemotherapy.
  • Approval follows Priority Review under FDA's Project Orbis initiative.

The big picture

This approval solidifies DATROWAY's role in treating aggressive TNBC, addressing a critical unmet need for 70% of patients ineligible for immunotherapy. The FDA's Project Orbis framework highlights the global urgency for effective cancer treatments. AstraZeneca and Daiichi Sankyo are now positioned to expand DATROWAY's reach across multiple tumor types and treatment settings.

What we're watching

Market Expansion
Whether DATROWAY can maintain its clinical advantage in broader TNBC populations beyond the trial cohort.
Regulatory Momentum
The pace at which other international regulators approve DATROWAY under Project Orbis.
Competitive Positioning
How AstraZeneca and Daiichi Sankyo position DATROWAY against emerging TNBC therapies.